91P Preexisting tumor host immunity delineates clinical outcomes in resectable non-small cell lung cancer

P. Rocha,M. Rodrigo,L. Moliner,A. Ríos-Hoyo, L. Masfarré, N. Navarro-Gorro,S. Menendez, A. Taus, A. Rodríguez, R. Aguiló, J. Belda,R. Del Rey-Vergara, M. Galindo,L. Comerma,E. Arriola

ANNALS OF ONCOLOGY（2022）

引用 0|浏览3

暂无评分

摘要

Neoadjuvant and adjuvant immune checkpoint blockade (ICB) have recently shown promising results in resectable NSCLC. Yet, biomarkers that inform patient benefit with this approach remain largely unknown. Here, we interrogated the tumor immune microenvironment (TIME) in early-stage NSCLC patients that underwent up-front surgery.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要